


STUDY PROTOCOL

Open Access



E-cigarette puffing patterns associated with high and low nicotine e-liquid strength: effects on toxicant and carcinogen exposure

Sharon Cox^{1*} , Leon Kośmider², Hayden McRobbie³, Maciej Goniewicz⁴, Catherine Kimber⁵, Mira Doig⁶ and Lynne Dawkins¹

Abstract

Background: Contrary to intuition, use of lower strength nicotine e-liquids might not offer reduced health risk if compensatory puffing behaviour occurs. Compensatory puffing (e.g. more frequent, longer puffs) or user behaviour (increasing the wattage) can lead to higher temperatures at which glycerine and propylene glycol (solvents used in e-liquids) undergo decomposition to carbonyl compounds, including the carcinogens formaldehyde and acetaldehyde. This study aims to document puffing patterns and user behaviour associated with using high and low strength nicotine e-liquid and associated toxicant/carcinogen exposure in experienced e-cigarette users (known as vapers herein).

Methods/design: A counterbalanced repeated measures design. *Participants:* Non-tobacco smoking vapers; have used an e-cigarette for ≥ 3 months; currently using nicotine strength e-liquid ≥ 12 mg/mL and a second or third generation device. *Intervention:* This study will measure puffing patterns in vapers whilst they use high and low strength nicotine e-liquid under fixed and user-defined settings, each for a week. The 4 counterbalanced conditions are: i) low strength (6mg/mL), fixed settings; ii) low strength user-defined settings; iii) high strength (18mg/mL) fixed settings; iv) high strength user-defined settings. Biomarkers of exposure to toxicants and carcinogens will be measured in urine. In the second phase of this study, toxicant yields will be measured in aerosol generated using a smoking machine operated to replicate the puffing behaviours of each participant. *Primary outcomes:* i) Puffing patterns (mean puff number, puff duration, inter-puff interval and mL of liquid consumed) and user behaviour (changes to device settings: voltage and air-flow) associated with using high and low strength nicotine e-liquid. ii) Toxicant/carcinogen exposure associated with the puffing patterns/device settings used by our participants. *Secondary outcomes:* i) Subjective effects. ii) comparisons with toxicant exposure from tobacco smoke (using documented evidence) and with recommended safety limits. *Sample size:* Twenty participants.

Discussion: The findings will have important implications for public health messaging regarding the relative risks and subjective effects associated with using high and low strength nicotine e-liquid, and for policy makers regarding regulations on nicotine concentrations in e-liquids.

Keywords: Electronic-cigarette, ENDS, E-cigarettes, Nicotine, Puffing patterns, Puffing topography, E-liquids, Toxicants, Carcinogens

* Correspondence: Ccox15@lsbu.ac.uk

¹London South Bank University, Division of Psychology, School of Applied Sciences, 103 Borough Rd, London, UK

Full list of author information is available at the end of the article



Background

Electronic cigarette (known as e-cigarettes, ENDS and e-cigs) use is becoming increasingly popular among smokers wishing to quit or reduce smoking [1]. The rise in popularity may in part be driven by consumer demand for a less harmful alternative to smoking tobacco and/or a desire to reduce nicotine intake. Indeed, the often flavoured e-liquid offers a range of nicotine strengths from 0 % to 2.0 % = 20 mg/mL (since the implementation of the EU Tobacco Products Directive), thus providing a new way for users to monitor and reduce their nicotine intake in a less ambiguous manner than traditional cigarettes.

Smokers and vapers may opt for, or switch to, lower nicotine strength e-liquid for a variety of reasons: the belief that it is healthier; desire to wean off nicotine; or due to the EU Tobacco Products Directive which stipulates an upper limit of 20mg/mL nicotine concentrations in e-liquids introduced in May 2016. However, contrary to intuition, use of lower strength nicotine e-liquids might not offer reduced health risk if compensatory puffing behaviour occurs.

Compensatory puffing behaviour is well documented in tobacco smokers. Smokers increase puff frequency, duration and volume when switching to a lower nicotine yield cigarette [2–4] whilst maintaining high blood nicotine levels [5, 6]. Exposure to tar in smoke known to contain carcinogenic compounds is consequently increased [2, 7]. Compared with vapers, smokers typically take shorter puffs [8] and after switching to vaping, can adjust their puffing patterns within a week [8, 9]. Two small scale laboratory studies suggest that vapers can also compensate for lower nicotine strength e-liquid by altering their puffing patterns. Ramôa and colleagues [10], using a ten-puff protocol, reported that vapers took larger and deeper puffs with 0mg/mL vs. 36mg/mL nicotine strength e-liquid, which the authors concluded may reflect an attempt to self-titrate due to the absence of nicotine. Similarly, we Dawkins et al. [11] observed compensatory puffing patterns in which vapers took longer, more frequent puffs, and doubled the amount of e-liquid consumed during a one-hour *ad lib* puffing period with a low (6mg/mL) compared with a high (24mg/mL) strength nicotine e-liquid. In this study the device settings (voltage, wattage, resistance of the coil and air-flow) were fixed reflecting standard second-generation devices. In reality, experienced users may adjust these parameters when using lower nicotine strength e-liquid and this may in turn, influence toxicant/carcinogen exposure. In the user-defined condition proposed here, we will allow users to adjust the voltage and air-flow of the device (although atomiser resistance will be kept constant).

Exposure to toxicants and carcinogens from e-cigarettes is 9–450 times lower than from tobacco cigarettes [12],

however, vaping is not risk-free and toxicant exposure will be related to the amount of e-liquid consumed. Longer, more frequent puffs and higher power may also lead to higher temperatures at which glycerine and propylene glycol, (solvents used in e-liquids), undergo decomposition to carbonyl compounds including the carcinogens formaldehyde and acetaldehyde [13]. If compensatory puffing patterns and changes to device settings lead to increased toxicant/carcinogen exposure due either to increased liquid consumption, increased temperature or both, switching to lower strength nicotine e-liquid may therefore not be the lower risk option.

We will measure puffing patterns in vapers in naturalistic conditions over four weeks whilst they use high and low strength nicotine e-liquid under fixed and user-defined (changes to device such as power output and air-flow allowed) settings, each for a week (4 conditions). Toxicant and carcinogen exposure will be assessed by measuring i) biomarkers of exposure in urine samples collected from participants and ii) yields of toxicants in e-cigarette aerosol generated for each individual under identical puffing conditions in the lab. Capturing e-cigarette puffing patterns and behaviour will not only inform the parameters of toxicity of the product used in the study but will have wider applicability for other researchers exploring toxicants/carcinogens in aerosol by ensuring realistic puffing patterns are used. Indeed, although the effects of solvent and power level on toxicant/carcinogen exposure have been explored [13, 14], laboratory studies to date have tested all products using the same puffing regime (ranging between studies from 1.8 to 4 s puff duration with a 10 to 60s inter-puff interval [IPI]; [13–17]). Such standardised puffing regimes not only fails to capture potential puffing variation between devices [18] and individuals [19, 20], but does not account for compensatory puffing with different nicotine yields [10, 11].

Whilst puffing patterns differed across high and low nicotine strength e-liquid conditions in our previous study, nicotine craving and withdrawal symptoms did not differ [11] suggesting that compensatory puffing behaviour was effective at least in the short term under laboratory conditions. Nevertheless, there was considerable individual variation on subjective reporting and laboratory conditions may not produce reliable evidence with respect to subjective effects because these settings can elicit unrealistic puffing behaviour [21]. The study outlined here will use a larger sample under naturalistic conditions to determine if and how real life puffing patterns associated with the use of high and low strength nicotine e-liquids differentially affect withdrawal symptoms, satisfaction and nicotine intake. Understanding the risks of compensatory puffing will have important implications for public health messaging regarding the relative risks and subjective effects associated with using high and low strength nicotine e-liquid, and for policy

makers regarding regulations on nicotine concentrations in e-liquids.

Objectives

This Cancer Research UK (CRUK) funded project will investigate e-cigarette puffing patterns and user behaviour associated with high and low strength nicotine e-liquids and how this affects toxicant and carcinogen exposure. We aim to measure natural consumer puffing behaviour in phase one of the experiment and to replicate these patterns within a laboratory setting within phase two. Specifically, we present four objectives:

- To measure puffing patterns (mean number of puffs, mean puff duration, mean IPI and mL liquid consumed) and user behaviour-changes to device settings - voltage and air-flow where permitted-associated with using high and low strength nicotine e-liquid to ascertain if and how compensatory puffing behaviour occurs.
- To explore if and how puffing patterns/user behaviour associated with high and low strength nicotine e-liquids affect satisfaction, craving, withdrawal symptoms and nicotine intake as measured by cotinine level in saliva.
- To determine whether puffing patterns/user behaviours associated with using low vs. high strength nicotine e-liquid increases toxicant/carcinogen exposure as measured by i) biomarker levels in users' urine and ii) toxicant yields in e-cigarette aerosol (as measured in a laboratory setting).
- To assess the risk of whether toxicant/carcinogen exposure levels associated with the puffing patterns/device settings used by our participants are at a level likely to affect human health by comparing these with those found in tobacco smoke and against recommended safety limits.

Study design

A repeated measured, counterbalanced, prospective cohort study.

Methods

Study setting

Figure 1 presents the study phases and stages.

Phase one

This study seeks to measure and replicate real-life puffing behaviours. Participants will receive minimal intervention in phase one of the study, only meeting with the research team on five occasions at baseline and at the end of each condition. Puffing data will be recorded by the e-cigarette device as participants complete their daily routines for the duration of phase one.

Puffing, biochemical and questionnaire data will be collected at London South Bank University within the School of Applied Sciences Psychology laboratories.

Urine and saliva samples will be sent off campus (see details below in Data collection) for analysis.

Phase two

Will replicate individual puffing topography from phase one, also at an external laboratory (see details below, in Data collection).

Eligibility criteria

Participants will be eligible to take part providing they are aged 18 or over, an ex-smoker (reporting having not smoked at all for at least 3 months, confirmed with a carbon monoxide reading in exhaled breath of < 10ppm) and a current, exclusive daily vaper, reporting e-cigarette use for ≥ 3 months. We have stipulated that current vapers should be using a nicotine strength e-liquid ≥ 12 mg/mL (1.2 %) with a second or third generation device (open-systems with re-fillable tanks). Participants




Fig. 1 Illustration of Phase one and Phase two and respective stages

Over the course of the 4 weeks, the e-cigarette will record puff number, puff duration, voltage, wattage and resistance. The device does not record puff velocity or volume, although these do not influence nicotine yield [20, 22]. Participants will be asked to refrain from using any other e-cigarette device, e-liquid or nicotine-containing products. We acknowledge that compliance may be an issue and will rely on participant's self-reports regarding non-compliance, deleting data from non-compliant days. Participants will return to the University after one week to collect the next batch of e-liquid and to provide subjective ratings, breath CO, saliva and urine samples. The researcher will download puffing and device setting information from the device and the tank will be thoroughly cleaned and the atomiser replaced, participants will be asked to report on how much e-liquid they have consumed over the week. This procedure will be repeated on three further occasions in order to capture information on puffing patterns subjective effects ratings and nicotine intake and toxicants in urine under each of four conditions.

All participants will start on fixed device settings (to allow familiarisation with the device before allowing participants to change setting), but we aim to counterbalance the nicotine condition by half of the participants starting on high strength 18mg/mL and half on low strength 6mg/mL. At the beginning of week two, participants will continue to use the device under fixed-settings but will be given a different strength of nicotine e-liquid (dependent on which they received in week 1). We may, if necessary, offer participants a week's break from the study during which time they can use their own device. If participant compliance and retention is an issue, we may recruit new participants for the second stage of phase one. In weeks 3 and 4, the counterbalancing of weeks 1 & 2 will be repeated under user-defined settings.

Primary outcomes

Phase one

To document real-life puffing patterns (mean puff number, puff duration, IPI and mL of e-liquid consumed) and user behaviour (voltage, air-flow) associated with using high (18mg/mL) and low strength (6mg/mL) nicotine e-liquid illustrating if and how compensatory puffing behaviour occurs.

Phase two

To record toxicant/carcinogen emissions associated with puffing patterns/user behaviours associated with using low vs. high strength nicotine e-liquid as measured by biomarker levels in users' urine and toxicant yields in e-cigarette aerosol.

Secondary outcomes

Phase one

Subjective ratings of satisfaction, craving, withdrawal symptoms as well as nicotine intake (measured with cotinine and calculated via mL of e-liquid consumed) under the four conditions.

Phase two

A comparison of toxicant/carcinogen exposure levels associated with the puffing patterns/device settings used by our participants with those found in tobacco smoke and against recommended safety limits using existing published material.

Participant timeline

Table 1 presents the participant timeline and associated interventions at each phase.

Sample Size

Twenty regular vapers will be recruited. The proposed sample size is based on puff number and puff duration results from Dawkins et al., ([11]: 2016) [7 : $N = 22$]. We observed effect sizes of $d = 0.74$ and $d = 1.09$ respectively. A sample of $N = 14$ for puff number and $N = 11$ for puff duration would allow us to detect effects at $p < 0.10$ with 90 % power.

Recruitment

An advert will be placed on London South Bank University's research participation scheme website, as well as advertisement in e-cigarette café's and on e-cigarette forums as well as via twitter and direct e-mail to known vapers.

Data collection

Phase one

Demographic information and vaping and previous smoking history will be collected via questionnaire at baseline assessment only.

At each session we will measure subjective craving ('urge to vape'), and withdrawal symptoms through the use of the Mood and Physical Symptoms Scale [23] Direct (e.g. hit, satisfaction) and Adverse (headache, nausea) effects relating to nicotine/e-cigarette use will be measured as previously described in [19]. All questionnaires will be presented in paper format. No permission is required to use any of these scales.

E-cigarette puffing patterns and user behaviour will be recorded by retrieving information on puff number, puff duration, voltage, wattage and resistance recorded by a third generation electronic cigarette provided to participants at the baseline assessment. Air flow settings are not recorded and we rely on participant self-report for

this information. Data will be downloaded from the participants' device and screened using myVapors software.

At all assessment phases we will measure exhaled carbon monoxide using the Bedfont Micro Smokerlyzer to ensure non-smoking status. Participants producing readings above 10ppm will be excluded from the analysis.

Saliva and urine samples will be taken from each participant at every study visit (5 per participant). These will be posted to ABS laboratories within 48 h of collection where they will be frozen at -20°C and stored until the end of the study. Saliva will be assayed for cotinine to determine nicotine intake and 3-hydroxy cotinine to determine CYP 2A6 levels (rate of nicotine metabolism). This will allow us to determine how successful compensatory puffing behaviour has been, controlling for nicotine metabolism rate if necessary. Urine will be assayed for 3-HPMA to show acrolein exposure. If the development of an LC-MS/MS method for estimation of formaldehyde exposure that is being performed to support another study is successful, the urine samples will also be assayed for formaldehyde exposure.

Phase two

In order to explore toxicant and carcinogen emission associated with these puffing patterns, at the second phase of the study puffing and device setting information collected from the participants will be used to create average puffing regimes for each person. This phase of the study will involve no human participants.

Within this second phase we will use the same e-cigarette device and e-Liquids as phase 1. Aerosol will be generated using the automatic smoking simulator, Palaczbot (previously used in several published studies; [24–27]), a single, linear unit that allows the generation of e-cigarette aerosols under specific conditions allowing us to mimic the puffing behaviours of each participant in each condition. Carbonyl compounds will be quantified using AT 1200 liquid chromatograph (Agilent Technologies: as described below) and nicotine using Gas chromatography method with Thermionic Specific Detector (GC-TSD, Varian Inc.)

Aerosol will be generated 3 (or 6 if necessary) times for each analysis (for nicotine or carbonyl compounds) to replicate each participant's puffing patterns using the same e-cigarette device setting under each of the four conditions in phase 1. Aerosol will be tested for formaldehyde, acetaldehyde, acrolein, benzaldehyde and nicotine emission with puffing regimes.

Carbonyl compounds (12 compounds): The method of aldehydes and ketones determination involves an adsorption of aldehydes and ketones aerosol mixture on a pipe filled with silica gel saturated with 2,4-dinitrophenylhydrazine, desorption of the compounds with acetonitrile in ultrasound washer, and determination using reverse phase technique of high performance liquid chromatography on

AT 1200 liquid chromatograph (Agilent Technologies) equipped with Zorbax Eclipse PAH column (4,6 x 250 mm, 5 μm) and spectrophotometric detector DAD. This allows determination of the following compounds: formaldehyde, acetaldehyde, acrolein, acetone, propionic aldehyde, crotonaldehyde, butanal, benzaldehyde, isovaleric aldehyde, valeric aldehyde, m-methylbenzaldehyde, o-methylbenzaldehyde, p-methylbenzaldehyde, hexanal, 2,5-dimethylbenzaldehyde [10].

Nicotine will be analysed using gas chromatography with Thermionic Specific Detector (GC-TSD, Varian Inc.). CP-Sil 8CB, 25 m x 0.25 mm x 0.39 mm (1.2 mm; Varian Inc.) capillary column with flow rate of helium of 2.4 ml/min will be used. Temperature of injector and detector will be 300°C , column temperature will be increased from 60 to 200°C ($20^{\circ}\text{C}/\text{min}$) and will be held for 5 min. Injection volume will be 1microlitre, and quinoline will be used as an internal standard.

Statistical methods

For each participant in each of the four conditions, mean puff duration, puff number, and (for the user-defined conditions) wattage, voltage and air-flow for each day will be calculated and averaged across the seven days (or reduced for the number of compliant days if necessary) for that participant and condition. Repeated measures Analysis of Variance (ANOVA) will be used to compare puff duration, puff number, wattage, voltage, cotinine and acrolein across relevant conditions.

We will also present mean and standard deviations for carbonyl compounds and nicotine and use ANOVA to explore any effects of condition on these variables.

We will estimate health risks by comparing levels of toxicant and carcinogen exposure to a) tobacco smoking (documented in the literature) and b) the Health and Safety Executive (HSE) workplace exposure limits [28] in order to provide useful information for public health professionals and policy makers about the relative harms associated with this level of exposure.

For each toxicant/carcinogen analysed, we will calculate a new exposure index (e-cigarette exposure index, EEI), i.e. total doses inhaled by individuals from e-cigarettes over one day. The EEI for each toxicant will be calculated by comparing doses inhaled from e-cigarette to doses that would be inhaled from air with toxicant concentration specified by the HSE long-term exposure limits. We will assume an average lung ventilation rate and take into account number of puffs taken per day. The EEI index may be useful to compare relative risk of inhaling toxicants from e-cigarettes. EEIs higher than 1.0 would indicate that mean exposures from e-cigarettes exceed exposure defined by HSE standards. We will verify if there is a correlation between the calculated EEI generated from the aerosol analysis with 3-HMPA concentration and

(if assay is successful) formaldehyde estimated in urine. The higher EEL, the higher health risk for users associated with inhaling specific toxicants.

Ethical considerations

Ethical approval was granted by London South Bank University (Application reference: UREC 1604) and has been funded by Cancer Research UK (Application reference: C50878/A21130). Informed consent will be collected in writing at the baseline session at the University prior to any data collection. Participants will have already received the information sheet and consent form via e-mail and had a chance to discuss any aspect of the study via e-mail or over the telephone with the researcher.

No sensitive data will be transferred electronically; it will also be anonymised beforehand (i.e. numerical codes will be used rather than names).

Discussion

The aim of this research is to investigate real-life e-cigarette puffing patterns and user behaviour associated with high and low strength nicotine e-liquids and how this affects toxicant and carcinogen exposure.

There are notable factors which will challenge the process of gaining the necessary evidence. The first relates to recruitment and retention. We are seeking experienced vapers with >3 months experience; we may expect vapers with such experience to be attached to their current devices, settings and e-liquid strengths and flavours and therefore not forthcoming in sampling new products and e-liquids. In order to mitigate this we have budgeted for wide advertisement of the study and allowed 7 months for recruitment and complete testing of 20 participants. Furthermore, we wish to measure long-term puffing patterns (over 4 weeks) beyond the timescale of previous research [8, 11, 29, 30]. For the same reasons highlighted above, participants may not be fully compliant, and may quit during our trial or (especially during the low nicotine strength weeks) compensate with their own devices or with cigarette smoking. We seek to overcome this by a) discussing flavour requirements and offering a range of e-liquid flavours, b) encouraging contact with the research team throughout the study c) emphasising honest reporting about non-compliance/use of other nicotine-containing products and d) recruiting exclusive vapers (non dual-users) who haven't smoked for at least 3 months. A seven day testing period under each condition means that we can exclude data from non-compliant days without it having a significant impact on our primary outcome, puffing patterns (puff number, duration, IPI and mL e-liquid consumed), which is essential for phase two. 3-HMPA (for acrolein exposure) and cotinine, with a half-life of 72 h and averaging 17 h respectively, [31, 32] may be more susceptible to the use of other nicotine-containing products

(especially to occasional tobacco cigarette smoking) but will we still be able to measure these in aerosol in phase two if non-compliance proves to be an issue. Finally, non-compliance itself is an interesting outcome and will still allow us to conduct meaningful analysis of toxicant/carcinogen exposure associated with different puffing regimes.

As in our laboratory study [11], we will use inbuilt e-cigarette software to capture information on puffing patterns, a straightforward and arguably, more ecologically valid procedure than CReSS pocket devices. This will provide us with detailed information on each puff (time of puff, length of puff), the IPI and overall number of puffs allowing us to exclude data from non-compliant days and to conduct more fine-grained analysis on the nature of puffing patterns (timings, cycles and episodes of puffs over 24 h periods) if necessary. However, the device does not record puff velocity or volume, although as noted earlier these parameters do not appear to influence nicotine yield [20, 22]. In the user-defined conditions, we will allow users to adjust the voltage (recorded for each puff by the device) and air-flow. The latter is not captured by the inbuilt software and we will therefore have to rely on participant self-report (average for the day) for this information. Experienced users may also be accustomed to adjusting the resistance of the atomiser/coil when switching to a lower nicotine strength e-liquid. We will request that participants do not change the atomiser on the device but if they do, the inbuilt software will record this information.

Although our study will not provide a definitive answer to the safety of e-cigarette use under all circumstances, it will help to inform public health messaging and policy making regarding the 'safest' way to vape and the regulation of nicotine e-liquid strengths. If compensatory puffing patterns associated with using lower nicotine strength e-liquids result in higher toxicant exposure, the use of higher nicotine strength e-liquids may be recommended. The findings will also provide the foundations for future studies exploring the effects of a broader range of e-cigarette devices, settings, nicotine strengths and flavourings on puffing patterns and help to inform the parameters of future aerosol toxicology studies.

The data collected are intended to benefit the general public; we will therefore preserve all data resulting from the study (with the exception of personal data) and make it publically available with as few restrictions as possible. We will disseminate a lay summary for participants, explaining our findings and their importance. Once the data has been finalized, it will be deposited in London South Bank University's open data repository. The findings will be disseminated via open access peer-review publication, conference presentations and press releases, and shared with a number of charities, practitioners and public health and policy organisations via presentations, briefing papers and web-based material.

Abbreviations

3-HPMA: 3-hydroxypropylmercapturic acid; EEI: Estimated Exposure Index; IPI: Inter-puff interval; LC-MS/MS: Liquid chromatography–mass spectrometry

Funding

This study is funded Cancer Research UK's Population Research Committee (Application reference: C50878/A21130). The funder did not play a role in the study design or contribution to the manuscript. As per the conditions of the grant application review process this study was peer-reviewed by CRUK.

Availability of data and materials

Not applicable.

Authors' contributions

LD is the Principal Researcher and grant holder for this project. Along with CK, LK and HMR, she conceived the original idea for the project and LD and CK collected the pilot study data. LD, LK, HMR, MG, designed the study, refined the methodology and contributed to the grant application. SC is responsible for the day-to-day running of the project and data collection. All authors contributed to and edited earlier drafts of this manuscript. All authors have read and approved the final manuscript.

Competing interests

SC has no conflict of interest to declare.

LK works in the Institute of Occupational Health and Environmental Medicine, an institution which, besides the research works, conducts analyses on behalf of industry, including the e-cigarette industry. The research design, analyses and interpretation of the results made within the scientific research are conducted independently from analyses served to the industry. He has no links with, and has not received any funds from, the tobacco or pharmaceutical industry.

HMR was an investigator on a study of e-cigarettes from an e-cigarette manufacturer (Ruyan Group, Beijing and Hong Kong). Ruyan supplied the e-cigarettes used in the trial and contracted with Health NZ Ltd. to undertake the study. Health New Zealand Ltd funded The University of Auckland to conduct the trial, independently of Ruyan Group (Holdings) Ltd. The trial design conduct, analysis and interpretation of results were conducted independently of the sponsors. HMR was also an investigator on the ASCEND e-cigarette trial funded by the Health Research Council of New Zealand that used product supplied at no charge from PGM international, a retailer of e-cigarettes.

MG received a research grant from Pfizer and served as an advisory board member to Johnson & Johnson, manufacturers of smoking cessation medications. He has no conflict of interests with the tobacco or e-cigarette industry.

CK has no conflict of interest to declare. MD is Director of ABS Laboratories which will be conducting the biomarker assay service for phase one of this study. She has no other conflict of interest to declare.

LD has conducted research for several independent electronic cigarette companies for which the University of East London has received funds. The e-cigarette companies involved had no input into the design, conduct or write up of these projects and she has not received any funds from e-cigarette companies in the last three years. She has also acted as an expert witness on an e-cigarette patent infringement case and consulted for the pharmaceutical industry (2015). She has no links with, and has not received any funds from the tobacco industry although two e-cigarette companies that she worked with in 2013 were subsequently acquired by the tobacco industry (SKYCIGs and E-Lites).

Ethics approval and consent to participate

Ethical approval was granted by London South Bank University (Application reference: UREC 1604) and has been funded by Cancer Research UK (Application reference: C50878/A21130).

Current status

Participant recruitment is due to begin in September 2016. Study findings are likely to be available from July 2017.

Author details

¹London South Bank University, Division of Psychology, School of Applied Sciences, 103 Borough Rd, London, UK. ²Institute of Occupational Medicine and Environmental Health, Koscielna 13 Street, Sosnowiec, Poland. ³Queen

Mary University of London, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, Charterhouse Square, London, UK. ⁴Roswell Park Cancer Institute, Department of Health Behavior, Elm and Carlton Streets, Buffalo, NY 14263, USA. ⁵University of East London, School of Psychology, Waters Lane, London, UK. ⁶ABS Laboratories Ltd, BioPark, Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AX, UK.

Received: 27 August 2016 Accepted: 9 September 2016

Published online: 20 September 2016

References

1. Action on Smoking and Health (ASH). Ash fact sheet: Use of electronic cigarettes (vapourisers) among adults in Great Britain. 2016. www.ash.org.uk/files/documents/ASH_891.pdf. Accessed 26 Aug 2016.
2. Herning RI, Jones RT, Bachman J, Mines AH. Puff volume increases when low-nicotine cigarettes are smoked. *Br Med J (Clin Res Ed)*. 1981;18:187–9.
3. Strasser AA, Lerman C, Sanborn PM, Pickworth WB, Feldman EA. New lower nicotine cigarettes can produce compensatory smoking and increased carbon monoxide exposure. *Drug Alc Depend*. 2007;86:294–300.
4. Woodward M, Tunstall-Pedoe H. Self-titration of nicotine: evidence from the Scottish Heart Health Study. *Addiction*. 1993;88:821–30.
5. Ashton H, Watson DW. Puffing frequency and nicotine intake in cigarette smokers. *Br Med J*. 1970;3:679–81.
6. Benowitz NL, Jacob P. Nicotine and carbon monoxide intake from high and low yield cigarettes. *Clin Pharmacol Ther*. 1984;36:265–70.
7. Smith CJ, Perfetti TA, Garg R, Hansch C. IARC carcinogens reported in cigarette mainstream smoke and their calculated log *P* values. *Food Chem Toxicol*. 2003;41:807–17.
8. Lee YH, Gawron M, Goniewicz ML. Changes in puffing behavior among smokers who switched from tobacco to electronic cigarettes. *Addict Behav*. 2015;9:1–4.
9. Hua M, Yip H, Talbot P. Mining data on usage of electronic nicotine delivery systems (ENDS) from YouTube videos. *Tob Control*. 2013;22(2):103–6.
10. Ramôa CP, Hiler MM, Spindle TR, Lopez AA, Karaoghlanian N, Lipato T, Breland AB, Shihadeh A, Eissenberg T. Electronic cigarette nicotine delivery can exceed that of combustible cigarettes: a preliminary report. *Tob Control*. 2015;25(e1):e6–9.
11. Dawkins L, Lynne E, et al. "Self-titration by experienced e-cigarette users: blood nicotine delivery and subjective effects." *Psychopharmacology*. 2016;233:1–9.
12. Goniewicz ML, Knysak J, Gawron M, Kosmider L, Sobczak A, Kurek J, et al. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. *Tob Control*. 2014;23(2):133–9.
13. Kosmider L, Sobczak A, Fik M, Knysak J, Zacierka M, Kurek J, Goniewicz ML. Carbonyl Compounds in Electronic Cigarette Vapors: Effects of Nicotine Solvent and Battery Output Voltage. *Nic Tob Res*. 2014;16(10):1319–26. 16.
14. Farsalinos KE, Voudris V, Poulas K. E-cigarettes generate high levels of aldehydes only in 'dry puff' conditions. *Addiction*. 2015;110(8):1352–6.
15. Farsalinos KE, Kistler KA, Gillman G, Voudris V. Evaluation of electronic cigarette liquids and aerosol for the presence of selected inhalation toxins. *Nic Tob Res*. 2015;17(2):168–74.
16. Jensen RP, Luo W, Pankow JF, Strongin RM, Peyton DH. Hidden formaldehyde in e-cigarette aerosols. *NEJM*. 2015;372(4):392–4.
17. Schripp T, Markewitz D, Uhde E, Salthammer T. Does e-cigarette consumption cause passive vaping? *Indoor Air*. 2013;23(1):25–31.
18. Dawkins L, Kimber C, Puwanesarasa Y, Soar K. First-versus second-generation electronic cigarettes: predictors of choice and effects on urge to smoke and withdrawal symptoms. *Addiction*. 2015;110(4):669–77.
19. Dawkins L, Corcoran O. Acute electronic cigarette use: nicotine delivery and subjective effects in regular users. *Psychopharmacology (Berl)*. 2014;231(2):401–7.
20. Talih S, Balhas Z, Eissenberg T, Salman R, Karaoghlanian N, El Hellani A, Baalbaki R, Saliba N, Shihadeh A. Effects of user puff topography, device voltage, and liquid nicotine concentration on electronic cigarette nicotine yield: measurements and model predictions. *Nic Tob Res*. 2015;17(2):150–7.
21. Robinson RJ, Hensel EC, Morabito PN, Roundtree KA. Electronic Cigarette Topography in the Natural Environment. *PLoS One*. 2015;10(6):1–14.
22. Kosmider L, Madej D, Gawron M, Sobczak A. Influence of electronic cigarettes puffing regimes on amount of vaporized liquid. (In press).
23. West R, Hajek P. Evaluation of the mood and physical symptoms scale (MPSS) to assess cigarette withdrawal. *Psychopharmacology (Berl)*. 2004;177:195–99.
24. Kosmider L, Sobczak A, Prokopowicz A, Kurek J, Zacierka M, Knysak J, Smith D, Goniewicz ML. Cherry-flavoured electronic cigarettes expose users to the inhalation irritant, benzaldehyde. *Thorax*. 2016;71(4):376–7.

25. Kośmider L, Sobczak A, Szołtysek-Boldys I, Prokopowicz A, Skórka A, Abdulafeez O, Koszowski B. Assessment of nicotine concentration in electronic nicotine delivery system (ENDS) liquids and precision of dosing to aerosol. *Przegl Lek.* 2015;72(10):500–4.
26. Czogala J, Goniewicz ML, Fidelus B, Zielinska-Danch W, Travers MJ, Sobczak A. Secondhand exposure to vapors from electronic cigarettes. *nicotine & tobacco research.* 2014;16(6):655–62.
27. Goniewicz ML, Kuma T, Gawron M, Knysak J, Kosmider L. Nicotine levels in electronic cigarettes. *Nic Tob Res.* 2013;15(1):158–66.
28. HSE EH40/2005 Workplace exposure limits. http://www.aber.ac.uk/en/media/departmental/healthsafetyenvironment/EH40_2011.pdf. Accessed 14 Sep 2016.
29. Behar RZ, Talbot P. Puffing topography and nicotine intake of electronic cigarette users. *PLoS One.* 2015;10(2):e0117222.
30. Spindle TR, Breland AB, Karaoghlanian NV, Shihadeh AL, Eissenberg T. Preliminary results of an examination of electronic cigarette user puff topography: the effect of a mouthpiece-based topography measurement device on plasma nicotine and subjective effects. *Nic Tob Res.* 2014;19:ntu186.
31. Jarvis MJ, Russell MAH, Benowitz NL, Feyerabend C. Elimination of cotinine from body fluid: Implications for noninvasive measurement of tobacco smoke exposure. *AJPH.* 1988;78(6):696–8.
32. Etter JF, Due TV, Perneger TV. Saliva cotinine levels in smokers and nonsmokers. *AJEP.* 2000;151(3):251–8.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

